Phase 2 CF Trial Shows GLPG2737 Add-on with Orkambi Effective, Safe

Phase 2 CF Trial Shows GLPG2737 Add-on with Orkambi Effective, Safe

GLPG2737 Add-on Increases Effectiveness of Orkambi for Cystic Fibrosis, Phase 2 Results Show

JULY 6, 2018

BY ALICE MELÃO

 

IN NEWS.

Adding GLPG2737, Galapagos’ investigational CFTR corrector, to Vertex’s Orkambi (lumacaftor/ivacaftor) enhances the effectiveness of the treatment in cystic fibrosis patients with two copies of the F508del mutation, topline results from a Phase 2 trial show. Conducted at multiple sites in Germany, the Phase 2 PELICAN clinical trial (NCT03474042) evaluated the effectiveness, safety, and tolerability of the […] The post GLPG2737 Add-on Increases Effectiveness of Orkambi for Cystic Fibrosis, Phase 2 Results Show appeared first on Cystic Fibrosis News Today.

Read More